|
SLE patients
|
20
|
28
|
|
Age, median (range)
|
45 (22–64)
|
42 (22–69)
|
|
Sex, number (%) of females
|
17 (85)
|
24 (86)
|
|
Disease manifestations at study inclusion, number (%) of patients
|
|
Renal disease
|
2 (10)
|
8 (29)
|
|
Vasculitis
|
2 (10)
|
3 (11)
|
|
Arthritis
|
2 (10)
|
3 (11)
|
|
Interstitial lung disease
|
1 (5)
|
0 (0)
|
|
Haemolysis
|
1 (5)
|
1 (4)
|
|
Alopecia
|
3 (15)
|
1 (4)
|
|
Rash
|
2 (10)
|
3 (11)
|
|
Mucosal ulcers
|
3 (15)
|
3 (11)
|
|
Leucopenia
|
1 (5)
|
1 (4)
|
|
Serositis
|
0 (0)
|
1 (4)
|
|
Thrombocytopenia
|
0 (0)
|
1 (4)
|
|
SLEDAI, median (range)
|
4 (0–12)
|
5 (0–18)
|
|
HCs
|
10
|
11
|
|
Age, median (range)
|
33.5 (25–63)
|
34 (24–54)
|
|
Sex, number (%) of females
|
6 (60)
|
9 (82)
|
